KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Ratio: 2010-2025

Historic Equity Ratio for TherapeuticsMD (TXMD) over the last 11 years, with Sep 2025 value amounting to 0.71.

  • TherapeuticsMD's Equity Ratio rose 3.60% to 0.71 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.71, marking a year-over-year increase of 3.60%. This contributed to the annual value of 0.71 for FY2024, which is 4.26% up from last year.
  • Per TherapeuticsMD's latest filing, its Equity Ratio stood at 0.71 for Q3 2025, which was up 0.12% from 0.71 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Equity Ratio ranged from a high of 0.71 in Q3 2025 and a low of -1.05 during Q1 2022.
  • For the 3-year period, TherapeuticsMD's Equity Ratio averaged around 0.66, with its median value being 0.69 (2024).
  • Per our database at Business Quant, TherapeuticsMD's Equity Ratio crashed by 2,561.13% in 2022 and then skyrocketed by 425.92% in 2023.
  • Over the past 5 years, TherapeuticsMD's Equity Ratio (Quarterly) stood at -0.55 in 2021, then surged by 170.33% to 0.39 in 2022, then skyrocketed by 74.06% to 0.68 in 2023, then climbed by 4.26% to 0.71 in 2024, then grew by 3.60% to 0.71 in 2025.
  • Its Equity Ratio stands at 0.71 for Q3 2025, versus 0.71 for Q2 2025 and 0.70 for Q1 2025.